Top

Pediatric Rheumatology

Published in:

Open Access 01-12-2016 | Review

Behçet’s disease in children, an overview

Author: Isabelle Koné-Paut

Published in: Pediatric Rheumatology | Issue 1/2016

Abstract

Summary

BD is a systemic inflammatory disease with a variable vasculitis. Paediatric onset is very rare and carries a strong genetic component. Oral ulcers and fever of unknown origin are frequent at onset and difficult to distinguish from other inflammatory disorders; therefore, expert opinion is still mandatory to recognize the disease early. An international expert consensus has recently proposed new classification criteria for children with BD. The clinical spectrum of BD is heterogeneous and influenced by gender, ethnicity and country of residence. Young males have the worst prognosis with significantly more frequent neurological, ocular and vascular involvement. BD treatment is aimed at alleviating inflammation. Among all drugs, TNFα inhibitors have become a standard to control severe ocular, neurological and digestive system involvement.

Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRefPubMed

Behçet H. Über rezidivierende aphtose durch ein virus verursachte geschwüre am mund, am auge und an den genitalien. Derm Wschr. 1937;105:1152.

Zouboulis CC, Kotter I, Djawari D, et al. Epidemiological feature of adamantiades Behcet’s disease in Germany and in Europe. Yonsei Med J. 1997;38:411–22.CrossRefPubMed

Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, et al. Demographic and clinical properties of juvenile-onset Behçet’s disease: A controlled multicenter study. J Am Acad Dermatol. 2008;58(4):579–84.CrossRefPubMed

Yazici H, Ugurlu S, Seyahi E. Behçet’s disease, is it one condition? Clinic Rev Allerg Immunol. 2012;43:275–80.CrossRef

Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011;50(1):184–8.CrossRef

Koné-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. Clinical features of Behçet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132(4):721–5.CrossRefPubMed

Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol. 2003;42(5):346–51.CrossRefPubMed

Bonitsis NG, Luong Nguyen LB, LaValley MP, Papoutsis N, Altenburg A, Kötter I, et al. Gender-specific differences in Adamantiades-Behçet’s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology (Oxford). 2015;54(1):121–33.CrossRef

10.

Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67–73.

11.

International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.

12.

International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.CrossRef

13.

Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, et al. Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2015. doi: 10.1136/annrheumxdis-2015-208491.

14.

Shimizu T, Erlich GE, Inaba G, Hayashi K. Behçet’s disease. Sem Arthritis Rheum. 1979;8:223–60.CrossRef

15.

Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;21:1284–91.CrossRef

16.

Horie Y, Meguro A, Ota M, Kitaichi N, Katsuyama Y, Takemoto Y, et al. Association of TLR4 polymorphisms with Behcet’s disease in a Korean population. Rheumatology (Oxford). 2009;48(6):638–42.CrossRef

17.

Seoudi N, Bergmeier LA, Drobniewski F, Paster B, Fortune F. The oral mucosal and salivary microbial community of Behçet’s syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015;7:27150.PubMed

18.

Direskeneli H, Mumcu G. A possible decline in the incidence and severity of Behçet’s disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S86–90.PubMed

19.

Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol. 2011;128(3):655–64.CrossRefPubMed

20.

Touzot M, Cacoub P, Bodaghi B, Soumelis V, Saadoun D. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. Autoimmun Rev. 2015;14(5):370–5.CrossRefPubMed

21.

Koné-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al. Familial aggregation in Behçet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135(1):89–93.CrossRefPubMed

22.

Gül A, Inanç M, Ocal L, Aral O, Koniçe M. Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis. 2000;59(8):622–5.PubMedCentralCrossRefPubMed

23.

Barnes CG, Yazici H. Behçet’s syndrome. Rheumatology. 1999;38:1171–6.CrossRefPubMed

24.

Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887–900.CrossRef

25.

Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42(8):698–702.PubMedCentralCrossRefPubMed

26.

Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.PubMedCentralCrossRefPubMed

27.

Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci U S A. 2013;110(20):8134–9.PubMedCentralCrossRefPubMed

28.

Hughes T, Ture-Ozdemir F, Alibaz-Oner F, Coit P, Direskeneli H, Sawalha AH. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4T cells from patients with Behçet’s disease. Arthritis Rheumatol. 2014;66:1648–58.PubMedCentralCrossRefPubMed

29.

Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet’s disease: from East to West. Clin Rheumatol. 2010;29(8):823–33.CrossRefPubMed

30.

Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13:367–73.CrossRefPubMed

31.

Olivieri I, Leccese P, Padula A, Nigro A, Palazzi C, Gilio M, et al. High prevalence of Behçet’s disease in southern Italy. Clin Exp Rheumatol. 2013;31(3 Suppl 77):28–31.PubMed

32.

Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9.CrossRefPubMed

33.

Mohammad A, Mandl T, Sturfelt G, Segelmark M. Incidence, prevalence and clinical characteristics of Behcet’s disease in southern Sweden. Rheumatology (Oxford). 2013;52(2):304–10.CrossRef

34.

Kötter I, Vonthein R, Müller CA, Günaydin I, Zierhut M, Stübiger N. Behçet’s disease in patients of German and Turkish origin living in Germany: a comparative analysis. J Rheumatol. 2004;31(1):133–9.PubMed

35.

Atmaca L, Boyvat A, Yalcyndað FN, Atmaca-Sonmez P, Gurler A. Behcet disease in children. Ocul Immunol Inflamm. 2011;19:103–7.CrossRefPubMed

36.

Kim DK, Chang SN, Bang D, Lee ES, Lee S. Clinical analysis of 40 cases of childhood-onset Behçet’s disease. Pediatr Dermatol. 1994;11:95–101.CrossRefPubMed

37.

Krause I, Uziel Y, Guedj D, Mukamel M, Harel L, Molad Y, et al. Childhood Behçet’s disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38(5):457–62.CrossRef

38.

Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157(5):901–6.CrossRefPubMed

39.

Saadoun D, Wechsler B, Desseaux K, Le Thi HD, Amoura Z, Resche-Rigon M, et al. Mortality in Behcet’s disease. Arthritis Rheum. 2010;62:2806–12.CrossRefPubMed

40.

Bahabri S, Al Mazyed A, Al Balaa S, El Rhamani A, Al Dalaan A. Juvenile Behcet’s disease in Arab children. Clin Exp Rheumatol. 1996;14:331–5.PubMed

41.

Seyahi E, Karaaslan H, Ugurlu S, Yazici H. Fever in Behçet’s syndrome. Clin Exp Rheumatol. 2013;31(3 Suppl 77):64–7.PubMed

42.

Cantarini L, Vitale A, Bersani G, Nieves LM, Cattalini M, Lopalco G, et al. PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clin Rheumatol. 2015 Feb 10. [Epub ahead of print].

43.

Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: A large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol. 2005;52:500–8.CrossRefPubMed

44.

Bang D, Hur W, Lee ES, Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behcet’s disease. J Dermatol. 1995;22:926–9.CrossRefPubMed

45.

Benamour S, Zeroual B, Alaoui FZ. Joint manifestations in Behçet’s disease. A review of 340 cases. Rev Rhum Engl Ed. 1998;65(5):299–307.PubMed

46.

Khairallah M, Attia S, Yahia SB, Jenzeri S, Ghrissi R, Jelliti B, et al. Pattern of uveitis in Behçet’s disease in a referral center in Tunisia. North Africa Int Ophthalmol. 2009;29(3):135–41.CrossRefPubMed

47.

Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behçet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114–9.CrossRefPubMed

48.

Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–80.CrossRefPubMed

49.

Pivetti-Pezzi P, Accorinti M, Abdulaziz MA, La Calva M, Torella M, Riso D. Behçet’s disease in children. Jpn J Ophtalmol. 1995;39:309–14.

50.

Noel N, Hutié M, Wechsler B, Vignes S, Le Thi Huong-Boutin D, Amoura Z, et al. Pseudotumoural presentation of neuro-Behcet’s disease: case series and review of literature. Rheumatology (Oxford). 2012;51(7):1216–25.CrossRef

51.

Vishwanath V, Wong E, Crystal SC, Robbins MS, Filopoulos M, Lipton RB, et al. Headache in Behçet’s syndrome: review of literature and NYU Behçet’s syndrome centre experience. Curr Pain Headache Rep. 2014;18(9):445.CrossRefPubMed

52.

Koné-Paut I, Chabrol B, Riss JM, Mancini J, Raybaud C, Garnier JM. Neurologic onset of Behçet’s disease : a diagnostic enigma in childhood. J Child Neurol. 1997;12:237–41.CrossRefPubMed

53.

Metreau-Vastel J, Mikaeloff Y, Tardieu M, Koné-Paut I, Tran TA. Neurological involvement in paediatric Behçet’s disease. Neuropediatrics. 2010;41(5):228–34.CrossRefPubMed

54.

Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum. 2012;64(8):2753–60.CrossRefPubMed

55.

Alibaz-Oner F, Karadeniz A, Ylmaz S, Balkarl A, Kimyon G, Yazc A, et al. Behçet disease with vascular involvement: Effects of different therapeutic regimens on the incidence of new relapses. Medicine. 2015;94(6):e494.PubMedCentralCrossRefPubMed

56.

Krupa B, Cimaz Z, Ozen S, Fischbach M, Cochat P, Koné-Paut I. Paediatric Behçet’s disease and thromboses. J Rheumatol. 2011;38(2):387–90.CrossRefPubMed

57.

Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35–48.CrossRef

58.

Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behcet’s disease. Intractable Rare Dis Res. 2015;4(2):70–5.PubMedCentralCrossRefPubMed

59.

Ozen S. The “other” vasculitis syndromes and kidney involvement. Pediatric Nephrol. 2010;25(9):1633–9.CrossRef

60.

Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656–62.

61.

Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443–50.CrossRefPubMed

62.

Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Ozturk BN, Mat C, et al. Apremilast for Behcet’s syndrome —a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510–8.CrossRefPubMed

63.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.CrossRefPubMed

64.

Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–6.CrossRefPubMed

65.

Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, Özyazgan Y, et al. Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study. Ocul Immunol Inflamm. 2016;30:1–9.CrossRef

66.

Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford). 2013;52(10):1923–4.CrossRef

67.

Addimanda O, Pipitone N, Pazzola G, Salvarani C. Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin Arthritis Rheum. 2015;44(4):472–5.CrossRefPubMed

68.

Tayer-Shifman OE, Seyahi E, Nowatzky J, et al. Major vessel thrombosis in Behcet’s disease: the dilemma of anticoagulant therapy- the approach of rheumatologists from different countries. Clin Exp Rheumatol. 2012;30:735–40.PubMed

Title: Behçet’s disease in children, an overview
Author: Isabelle Koné-Paut
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Pediatric Rheumatology / Issue 1/2016
Electronic ISSN: 1546-0096
DOI: https://doi.org/10.1186/s12969-016-0070-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Behçet’s disease in children, an overview

Abstract

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Please log in to get access to this content

Other articles of this Issue 1/2016

Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis

The human microbiome and juvenile idiopathic arthritis

The difference of disease perception by juvenile idiopathic arthritis patients and their parents: analysis of the JAMAR questionnaire

Paediatric musculoskeletal matters (pmm) – collaborative development of an online evidence based interactive learning tool and information resource for education in paediatric musculoskeletal medicine

Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population

Reviewer acknowledgement 2015